期刊
EUROPEAN JOURNAL OF PHARMACOLOGY
卷 895, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ejphar.2021.173862
关键词
Parkinson's disease; Estrogen replacement therapy; Neuroendocrine; Therapeutic strategies; Molecular; Genetic
资金
- Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India
- CSIR
Parkinson's disease is less prevalent in women compared to men, but this difference tends to diminish with age. Various genetic, hormonal, and molecular factors contribute to the differences in the pathogenesis of Parkinson's disease.
Parkinson's disease is a neurodegenerative disease which is associated with different motor, cognitive and mood-related problems. Though it has been established that Parkinson's disease is less prevalent in women in comparison to men, the differences tend to diminish with the advancing age. Different genetic, hormonal, neuro-endocrinal and molecular players contribute towards the differences in the Parkinson's disease pathogenesis. Furthermore, data available with respect to the therapeutic management of Parkinson's disease in females is limited; women often tend to suffer more from the side effects of the currently available drugs. The present review highlights the sex-specific differences which play a role in the manifestation of these symptoms and side effects of the currently available therapeutic strategies. We have also discussed the current and upcoming therapeutic strategies which are in the clinical trials such as adenosine 2A (A2A) receptor antagonists, estrogen replacement therapy, alpha-synuclein targeting vaccines and antibodies, Botulinum toxin A, Fas-associated factor-1 (FAF-1) inhibitors, thiazolidinediones, 5-HT1(A) receptor agonists, dopamine D1/D5 receptor agonists, Glucagon-like peptide 1 (GLP-1) analogues and certain plant based principles for the treatment of Parkinson's disease in women.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据